

12.³ The method of claim 3¹ wherein said pathogenic *Mycoplasma* bacteria is a member of the genus *Mycoplasma*.

13. The method of claim 12 wherein said bacteria is selected from the group consisting of: *Mycoplasma hominis* and *Mycoplasma fermentans*.

14. The method of claim 12 wherein said bacteria is selected from the group consisting of: *Mycoplasma pneumoniae*, *Mycoplasma genitalium*, and *Mycoplasma penetrans*.

15. The method of claim 3¹ wherein said bacteria is a member of the genus *Ureaplasma*.

16. The method of claim 15 wherein said bacteria is *Ureaplasma urealyticum*.

17.²³ The method according to claim 3¹ wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

18.²⁴ The method according to claim 17²³ wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

19.²⁵ The method according to claim 18²⁴ wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

20.¹² The method according to claim 12³ wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

21.¹³ The method according to claim 20¹² wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

22.¹⁴ The method according to claim 21¹³ wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

23.⁵ The method according to claim 13⁴ wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

24.⁶ The method according to claim 23⁵ wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

25.⁷ The method according to claim 24⁶ wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

26.⁹ The method according to claim 14⁸ wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

09/399,855-051101